Which is NOT listed as an IL-23 inhibitor in the source?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Prepare for the CMS II Rheumatology E1 Exam with our comprehensive quiz. Study using flashcards and multiple-choice questions, each with hints and explanations. Get ready for success!

Multiple Choice

Which is NOT listed as an IL-23 inhibitor in the source?

Explanation:
IL-23 inhibitors block the p19 subunit specific to IL-23, cutting IL-23 signaling while largely preserving IL-12. Drugs like guselkumab, tildrakizumab, and risankizumab all target that p19 subunit, so they are IL-23–specific inhibitors. Ustekinumab, however, binds the p40 subunit shared by both IL-12 and IL-23, reducing activity of both cytokines rather than IL-23 alone. Because the question asks for the one not listed as an IL-23 inhibitor, the correct choice is ustekinumab.

IL-23 inhibitors block the p19 subunit specific to IL-23, cutting IL-23 signaling while largely preserving IL-12. Drugs like guselkumab, tildrakizumab, and risankizumab all target that p19 subunit, so they are IL-23–specific inhibitors. Ustekinumab, however, binds the p40 subunit shared by both IL-12 and IL-23, reducing activity of both cytokines rather than IL-23 alone. Because the question asks for the one not listed as an IL-23 inhibitor, the correct choice is ustekinumab.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy